โ† All deals

NewcelX Ltd.

BiotechnologyBiotechnologyCell TherapyPublic Company
๐Ÿ“ Kloten, Zurich, Switzerlandโ€ข Founded 2009
StreetZero Signal 73
Be the first to signal interest

About NewcelX Ltd.

NewcelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was established through the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., combining advanced stem-cell technologies with neuroscience expertise. It is headquartered in Kloten, Zurich, Switzerland, and operates as a public company listed on NASDAQ under the ticker NCEL. Its main program focuses on cell replacement therapies, including for Type 1 Diabetes and ALS.

LATEST FUNDINGPrivate Placement
$2.9M
Announced 2026-11-18
TOTAL RAISED$2.75M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for NewcelX Ltd..

Free plan includes 3 full deal profiles every month.

EMPLOYEESโ€”
FOUNDED2009
HQKloten, Zurich, Switzerland
Industry
Biotechnology
Tags
BiotechnologyCell TherapyPublic CompanyRegenerative Medicine

Investors

Not disclosed in the source filing. Form D filings do not list investors โ€” StreetZero surfaces them from news where available.

Key highlights

  • Established via merger of NLS Pharmaceutics and Kadimastem to advance combined cell-therapy and neuroscience platforms.
  • Raised $2.875M in private placement alongside $9M in related equity financing and warrant exercises.
  • Clinical-stage programs target ALS and Type 1 Diabetes using human pluripotent stem cell technology.
  • Headquartered in Kloten, Switzerland with NASDAQ listing under ticker NCEL.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account